Krones Ag Adr (KRNTY) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and a warm welcome to the Crohn's conference call. My name is Olaf Scholz. I'm head of investor relations here at Crohn's. We have had a good start into 2025, and so we continued our profitable growth path. With strong figures and an improvement in all key figures, we published our Q1 results in the morning. But nevertheless, there are also uncertainties in the world which could affect the world economy. Well, that's the situation. Christoph Klenk and Uta Anders will give you more details about these figures and will give you also additional information. After the presentation, you will have the opportunity to ask questions. I think you also know how the Q&A questions work. You can raise your hand over the Teams function or send me just a short email. Additional, please be reminded that this meeting will not be recorded. So please also deactivate any functions of recording at Teams. I think let's start with the presentation. So I hand over to Christoph Klenk. Christoph, the floor is yours. I'm sorry. Thanks, Ola. Good afternoon. Welcome on behalf of the two of us here. Pleasure to have you here today and give you insights where we are after Q1 and how we see actually the perspective of Crohn's in 2025 and beyond. I can say before I start, we are quite pleased where we are. So the results are good and in line with our planning. And we come to that in a minute. And as always, I skip, let me say, the overviews and we jump immediately into the order intake, which might be one of the important topics where we are with this and how our outlook is in particular under the view of the tariffs we are facing in the US or we might face or might not face. um order intake as you can see at a bit above 1.4 billion we are quite heavy with the number we have achieved h...